1 |
16,5% cutaquig |
- |
- |
- |
- |
065 [1] 65 💬 |
2 |
36-482-hyaluronoglucosaminidase ph20 (rhuph20) |
Hyaluronidase |
[3] D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 [1] 65 💬 |
3 |
[na] |
- |
- |
- |
- |
006 [7] 6 , 11, 35, 46, 53, 65, 299 💬 |
4 |
A10bk03 |
- |
- |
- |
- |
065 [1] 65 💬 |
5 |
Abatacept |
Abatacept |
[1] D03203 D03203 💬 |
CD80 [2] CD80, CD86 💬 |
Allograft rejection [12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
011 [26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |
6 |
Acoziborole (scyx-7158) |
SCYX-7158 |
- |
- |
- |
065 [1] 65 💬 |
7 |
Ada gene transfer |
- |
- |
- |
- |
065 [1] 65 💬 |
8 |
Ada pbsc |
- |
- |
- |
- |
065 [1] 65 💬 |
9 |
Ada umbilical cord blood cells |
- |
- |
- |
- |
065 [1] 65 💬 |
10 |
Adagen |
- |
- |
- |
- |
065 [1] 65 💬 |
11 |
Adenosine |
Adenosine |
[1] D00045 D00045 💬 |
ADORA1 [4] ADORA1, ADORA2A, ADORA2B, ADORA3 💬 |
Alcoholism [12] Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [3] 13, 58, 65 💬 |
12 |
Administration of drug (interferon-gamma 1-b) subcutaneously |
- |
- |
- |
- |
065 [1] 65 💬 |
13 |
Adverse reactions of gammagard subcutaneously at week 12 |
- |
- |
- |
- |
065 [1] 65 💬 |
14 |
Adverse reactions of gammagard subcutaneously at week 24 |
- |
- |
- |
- |
065 [1] 65 💬 |
15 |
Adverse reactions of gammagard subcutaneously at week 36 |
- |
- |
- |
- |
065 [1] 65 💬 |
16 |
Adverse reactions of gammagard subdermally at week 12 |
- |
- |
- |
- |
065 [1] 65 💬 |
17 |
Adverse reactions of gammagard subdermally at week 24 |
- |
- |
- |
- |
065 [1] 65 💬 |
18 |
Adverse reactions of gammagard subdermally at week 36 |
- |
- |
- |
- |
065 [1] 65 💬 |
19 |
Aldesleukin |
Aldesleukin |
[1] D00748 D00748 💬 |
IL2RA [3] IL2RA, IL2RB, IL2RG 💬 |
Cytokine-cytokine receptor interaction [14] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
049 [4] 49, 65, 96, 97 💬 |
20 |
Alefacept |
Alefacept |
[1] D02800 D02800 💬 |
CD58 [1] CD58 💬 |
Cell adhesion molecules [2] Cell adhesion molecules, Epstein-Barr virus infection |
037 [6] 37, 60, 65, 164, 284, 285 💬 |
21 |
Alemtuzumab |
Alemtuzumab |
[1] D02802 D02802 💬 |
- |
- |
013 [16] 13, 15, 19, 20, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 💬 |
22 |
Alemtuzumab 0.2 mg |
Alemtuzumab |
[1] D02802 D02802 💬 |
- |
- |
065 [2] 65, 164 💬 |
23 |
Alemtuzumab 0.3 mg |
Alemtuzumab |
[1] D02802 D02802 💬 |
- |
- |
065 [2] 65, 164 💬 |
24 |
Alentuzumab (campath) |
- |
- |
- |
- |
065 [1] 65 💬 |
25 |
Allogeneic peripheral blood stem cell |
- |
- |
- |
- |
065 [1] 65 💬 |
26 |
Anti-cd45 |
- |
- |
- |
- |
060 [3] 60, 65, 285 💬 |
27 |
Anti-thymocyte globulin |
- |
- |
- |
- |
011 [18] 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 💬 |
28 |
Anti-thymocyte globulin (rabbit) |
Rabbit |
- |
- |
- |
060 [4] 60, 65, 96, 285 💬 |
29 |
Antithymocyte globulin |
- |
- |
- |
- |
060 [3] 60, 65, 284 💬 |
30 |
Aproart |
- |
- |
- |
- |
065 [1] 65 💬 |
31 |
Autologous cd34+ cell transduced with g2scid vector |
- |
- |
- |
- |
065 [1] 65 💬 |
32 |
Autologous cd34+ cells transduced ex-vivo with the pcclchimgp91/vsvg lentiviral vector |
- |
- |
- |
- |
065 [1] 65 💬 |
33 |
Autologous cd34+ cells transduced with the lentiviral vector containing the human wiskott aldrich sy |
- |
- |
- |
- |
065 [1] 65 💬 |
34 |
Autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with lentiviral vector that encodes for the human wiskott aldrich syndrome (was) cdna sequence |
- |
- |
- |
- |
065 [1] 65 💬 |
35 |
Autologous cd34+ hscs transduced ex vivo with efs lentiviral vector encoding for the human ada gene |
- |
- |
- |
- |
065 [1] 65 💬 |
36 |
Autologous cd34+cells transduced with the w1.6_hwasp_wpre (vsvg) lentiviral vector |
- |
- |
- |
- |
065 [1] 65 💬 |
37 |
Autologous ex vivo gene therapy products based on the efs lv encoding for the human adenosine deaminase (ada) gene (efs-ada lv) |
Adenosine |
[1] D00045 D00045 💬 |
ADORA1 [4] ADORA1, ADORA2A, ADORA2B, ADORA3 💬 |
Alcoholism [12] Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
065 [1] 65 💬 |
38 |
Azathioprine |
Azathioprine |
[2] D00238 D00238, D03033 D03033 💬 |
- |
- |
006 [20] 6 , 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 94, 95, 96, 97, 162 💬 |
39 |
B-lymphocyte stimulator (blys) |
- |
- |
- |
- |
065 [1] 65 💬 |
40 |
Bacteriophage |
- |
- |
- |
- |
065 [1] 65 💬 |
41 |
Basiliximab |
Basiliximab |
[1] D03058 D03058 💬 |
IL2RA [1] IL2RA 💬 |
Cytokine-cytokine receptor interaction [11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
002 [6] 2 , 50, 65, 97, 222, 228 💬 |
42 |
Benznidazole |
Benznidazole |
[1] D02489 D02489 💬 |
- |
- |
065 [1] 65 💬 |
43 |
Biological sampling |
- |
- |
- |
- |
065 [1] 65 💬 |
44 |
Bivigam |
- |
- |
- |
- |
065 [1] 65 💬 |
45 |
Bms-188667 |
- |
- |
- |
- |
046 [8] 46, 49, 53, 65, 96, 97, 222, 271 💬 |
46 |
Bpx-501 t cells |
- |
- |
- |
- |
065 [4] 65, 284, 285, 326 💬 |
47 |
Bt090 |
- |
- |
- |
- |
065 [1] 65 💬 |
48 |
Bt524 |
- |
- |
- |
- |
065 [1] 65 💬 |
49 |
Bt595 |
- |
- |
- |
- |
063 [2] 63, 65 💬 |
50 |
Bt681 |
- |
- |
- |
- |
065 [1] 65 💬 |
51 |
Busilvex |
- |
- |
- |
- |
019 [4] 19, 36, 60, 65 💬 |
52 |
Busilvex - 6 mg/ml - concentrato per soluzione per infusione - uso endovenoso - flaconcino - 10 ml 8 flaconcini |
- |
- |
- |
- |
019 [2] 19, 65 💬 |
53 |
Busulfan |
Busulfan |
[1] D00248 D00248 💬 |
- |
- |
019 [13] 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 💬 |
54 |
Busulfan iv |
Busulfan |
[1] D00248 D00248 💬 |
- |
- |
065 [1] 65 💬 |
55 |
Busulfan test dose |
Busulfan |
[1] D00248 D00248 💬 |
- |
- |
065 [1] 65 💬 |
56 |
Busulfan, cyclophosphamide, atg, gcsf |
Busulfan |
[3] D00248 D00248, D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [2] 65, 284 💬 |
57 |
Busulfan, fludarabine and atg |
Busulfan |
[3] D00248 D00248, D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [1] 65 💬 |
58 |
Busulfan, fludarabine, atg, tli |
Busulfan |
[3] D00248 D00248, D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [2] 65, 284 💬 |
59 |
C1 esterase inhibitor (human) |
- |
- |
- |
- |
065 [1] 65 💬 |
60 |
C1 esterase inhibitor human |
- |
- |
- |
- |
065 [1] 65 💬 |
61 |
C1 inhibitor |
Human C1-esterase inhibitor |
- |
- |
- |
065 [1] 65 💬 |
62 |
C1 inhibitor concentrate |
Human C1-esterase inhibitor |
- |
- |
- |
065 [1] 65 💬 |
63 |
C1-esterase inhibitor [recombinant] (c1-inh-r) |
Human C1-esterase inhibitor |
- |
- |
- |
065 [1] 65 💬 |
64 |
C1-inh |
Human C1-esterase inhibitor |
- |
- |
- |
065 [1] 65 💬 |
65 |
Campath |
- |
- |
- |
- |
019 [12] 19, 20, 49, 51, 60, 62, 65, 164, 234, 283, 285, 326 💬 |
66 |
Campath -1h |
- |
- |
- |
- |
065 [1] 65 💬 |
67 |
Campath 1h |
- |
- |
- |
- |
060 [4] 60, 65, 164, 285 💬 |
68 |
Campath, fludarabine, cyclophosphamide |
Cyclophosphamide |
[4] D00287 D00287, D01907 D01907, D07760 D07760, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [2] 65, 284 💬 |
69 |
Cd3/cd19 neg allogeneic bmt |
- |
- |
- |
- |
065 [1] 65 💬 |
70 |
Cd3/cd19 negative allogeneic hematopoietic stem cells |
- |
- |
- |
- |
065 [1] 65 💬 |
71 |
Cd34 stem cell selection therapy |
- |
- |
- |
- |
060 [3] 60, 65, 284 💬 |
72 |
Cd34+ |
- |
- |
- |
- |
065 [1] 65 💬 |
73 |
Cd34+ cells transduced with ada retrovir |
- |
- |
- |
- |
065 [1] 65 💬 |
74 |
Cd34+ hscs transduced with the lentivirus vector, vsv-g pseudotyped cl20-4i-ef1a-h?c-opt |
- |
- |
- |
- |
065 [1] 65 💬 |
75 |
Cd34+cells |
- |
- |
- |
- |
065 [2] 65, 285 💬 |
76 |
Cd45ra-depleted dli |
- |
- |
- |
- |
060 [2] 60, 65 💬 |
77 |
Cdz173 |
- |
- |
- |
- |
053 [2] 53, 65 💬 |
78 |
Chloride |
Chloride ion |
- |
- |
- |
006 [25] 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 97, 127, 168, 171, 193, 227, 228, 271, 288, 296, 297, 299 💬 |
79 |
Cryopreserved efs-ada lv transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
80 |
Cryopreserved g2scid lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
81 |
Cultured thymus tissue for implantation (ctti) |
- |
- |
- |
- |
065 [1] 65 💬 |
82 |
Cultured thymus tissue implantation (ctti) |
- |
- |
- |
- |
065 [1] 65 💬 |
83 |
Cutaquig |
- |
- |
- |
- |
065 [1] 65 💬 |
84 |
Cuvitru |
- |
- |
- |
- |
065 [1] 65 💬 |
85 |
Cuvitru 200 mg/ml solution for subcutaneous injection |
- |
- |
- |
- |
065 [1] 65 💬 |
86 |
Cyclophosphamide |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
011 [44] 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 💬 |
87 |
Cyclophosphamide (cytoxan) |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [1] 65 💬 |
88 |
Cyclophosphamide 30 |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [3] 65, 285, 326 💬 |
89 |
Cyclophosphamide 40 |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [3] 65, 285, 326 💬 |
90 |
Cyclophosphamide dose level 1 |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [2] 65, 284 💬 |
91 |
Cyclophosphamide dose level 2 |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [2] 65, 284 💬 |
92 |
Cyclophosphamide dose level 3 |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [2] 65, 284 💬 |
93 |
Cyclophosphamide dose level 4 |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [2] 65, 284 💬 |
94 |
Cyclophosphamide post transplant |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [1] 65 💬 |
95 |
Cyclosporine |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 [35] 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 63, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 💬 |
96 |
Cyclosporins |
- |
- |
- |
- |
053 [4] 53, 60, 65, 222 💬 |
97 |
Daclizumab |
Daclizumab |
[1] D03639 D03639 💬 |
IL2RA [1] IL2RA 💬 |
Cytokine-cytokine receptor interaction [11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
013 [7] 13, 56, 60, 65, 97, 283, 284 💬 |
98 |
Danazol |
Danazol |
[1] D00289 D00289 💬 |
AR [3] AR, ESR1, PGR 💬 |
Breast cancer [11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
060 [5] 60, 63, 64, 65, 285 💬 |
99 |
Data collection |
- |
- |
- |
- |
065 [1] 65 💬 |
100 |
Db289 |
- |
- |
- |
- |
065 [1] 65 💬 |
101 |
Depletion in cd45ra graft donor |
- |
- |
- |
- |
065 [1] 65 💬 |
102 |
Device: cell processing for tcrabeta+/cd19+ depletion |
- |
- |
- |
- |
065 [1] 65 💬 |
103 |
Device: cell processing for tcraß+/cd19+ depletion |
- |
- |
- |
- |
065 [1] 65 💬 |
104 |
Device: chrono super pid then generic syringe-gammanorm |
- |
- |
- |
- |
065 [1] 65 💬 |
105 |
Device: clinimacs |
- |
- |
- |
- |
060 [2] 60, 65 💬 |
106 |
Device: clinimacs® cd34 reagent system cell sorter device |
- |
- |
- |
- |
065 [1] 65 💬 |
107 |
Device: continuous glucose monitor |
Dextrose, unspecified form |
- |
- |
- |
065 [1] 65 💬 |
108 |
Device: generic syringe then chrono super pid-gammanorm |
- |
- |
- |
- |
065 [1] 65 💬 |
109 |
Device: isolex 300i magnetic cell selector |
- |
- |
- |
- |
065 [1] 65 💬 |
110 |
Device: miltenyi clinimacs |
- |
- |
- |
- |
062 [2] 62, 65 💬 |
111 |
Device: miltenyi clinimacs selection system |
- |
- |
- |
- |
065 [1] 65 💬 |
112 |
Device: unrelated pbsc with t cell depletion |
- |
- |
- |
- |
065 [1] 65 💬 |
113 |
Dexametasone fosfato sodico |
- |
- |
- |
- |
065 [1] 65 💬 |
114 |
Dexamethasone |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [25] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 162, 222, 235, 283, 296, 299 💬 |
115 |
Dexamethasone 21-dihydrogen phosphate |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
065 [1] 65 💬 |
116 |
Dexamethasone sodium phosphate |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
065 [3] 65, 70, 96 💬 |
117 |
Dexamethasone sodium phosphate ph. eur. |
Dexamethasone |
[9] D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
065 [1] 65 💬 |
118 |
Dextrose |
Dextrose, unspecified form |
- |
- |
- |
056 [4] 56, 60, 65, 70 💬 |
119 |
Dextrose, 5% in water |
Dextrose, unspecified form |
[1] D00001 D00001 💬 |
- |
- |
065 [1] 65 💬 |
120 |
Diagnostic test: blood drawing in healthy controls |
- |
- |
- |
- |
065 [1] 65 💬 |
121 |
Diagnostic test: blood drawing in patients with was |
- |
- |
- |
- |
065 [1] 65 💬 |
122 |
Diagnostic test: functional and antigenic c1 inhibitor |
Human C1-esterase inhibitor |
- |
- |
- |
065 [1] 65 💬 |
123 |
Diagnostic test: oral glucose tolerance test |
Dextrose, unspecified form |
- |
- |
- |
013 [3] 13, 65, 299 💬 |
124 |
Diagnostic test: rna and neopterin detection |
Neopterin |
- |
- |
- |
065 [1] 65 💬 |
125 |
Donor peripheral blood stem cells. |
- |
- |
- |
- |
065 [1] 65 💬 |
126 |
Ef1as-ada lentiviral vector gene modified autologous cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
127 |
Ef1as-ada lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
128 |
Efficacy of gammagard subcutaneously at week 12 |
- |
- |
- |
- |
065 [1] 65 💬 |
129 |
Efficacy of gammagard subcutaneously at week 24 |
- |
- |
- |
- |
065 [1] 65 💬 |
130 |
Efficacy of gammagard subcutaneously at week 36 |
- |
- |
- |
- |
065 [1] 65 💬 |
131 |
Efficacy of gammagard subdermally at week 12 |
- |
- |
- |
- |
065 [1] 65 💬 |
132 |
Efficacy of gammagard subdermally at week 24 |
- |
- |
- |
- |
065 [1] 65 💬 |
133 |
Efficacy of gammagard subdermally at week 36 |
- |
- |
- |
- |
065 [1] 65 💬 |
134 |
Eflornithine |
Eflornithine |
[1] D07883 D07883 💬 |
ODC1 [1] ODC1 💬 |
Arginine and proline metabolism [3] Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 [1] 65 💬 |
135 |
Eflornithine plus nifurtimox combination therapy |
Eflornithine |
[2] D00833 D00833, D07883 D07883 💬 |
ODC1 [1] ODC1 💬 |
Arginine and proline metabolism [3] Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 [1] 65 💬 |
136 |
Elapegademase |
Elapegademase |
[1] D11017 D11017 💬 |
ADA [1] ADA 💬 |
Metabolic pathways [3] Metabolic pathways, Primary immunodeficiency, Purine metabolism |
065 [1] 65 💬 |
137 |
Elapegademase-lvlr |
Elapegademase |
[1] D11017 D11017 💬 |
ADA [1] ADA 💬 |
Metabolic pathways [3] Metabolic pathways, Primary immunodeficiency, Purine metabolism |
065 [1] 65 💬 |
138 |
Eltrombopag |
Eltrombopag |
[1] D03978 D03978 💬 |
- |
- |
060 [5] 60, 63, 65, 284, 285 💬 |
139 |
Empagliflozin |
Empagliflozin |
[1] D10459 D10459 💬 |
- |
- |
065 [3] 65, 72, 257 💬 |
140 |
Ep2006 |
- |
- |
- |
- |
065 [1] 65 💬 |
141 |
Ep2006 (filgrastim) |
Filgrastim |
[1] D03235 D03235 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 [1] 65 💬 |
142 |
Etoposide |
Etoposide |
[2] D00125 D00125, D04107 D04107 💬 |
TOP2A [2] TOP2A, TOP2B 💬 |
Platinum drug resistance [1] Platinum drug resistance |
011 [11] 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 💬 |
143 |
Ex vivo culture and transduction of the patient's autologous cd34+ hsc with lentivirus vector vsv-g pseudotyped cl20- 4i-ef1a-hyc-opt vector |
- |
- |
- |
- |
065 [1] 65 💬 |
144 |
Ezn-2279 |
- |
- |
- |
- |
065 [1] 65 💬 |
145 |
Fansidar (pyrimethamine and sulfadoxine) |
Pyrimethamine |
[2] D00488 D00488, D00580 D00580 💬 |
- |
- |
065 [1] 65 💬 |
146 |
Fexinidazole |
Fexinidazole |
[1] D11252 D11252 💬 |
- |
- |
065 [1] 65 💬 |
147 |
Fibrinogen |
Fibrinogen human |
- |
- |
- |
014 [3] 14, 65, 288 💬 |
148 |
Fibrinogen (coagulation factori) |
Fibrinogen human |
- |
- |
- |
065 [1] 65 💬 |
149 |
Fibrinogen concentrate from human plasma |
Fibrinogen human |
- |
- |
- |
065 [1] 65 💬 |
150 |
Filgrastim |
Filgrastim |
[1] D03235 D03235 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 [27] 2 , 6 , 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 |
151 |
Filgrastim hexal |
Filgrastim |
[1] D03235 D03235 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 [1] 65 💬 |
152 |
Filgrastim, alemtuzumab |
Alemtuzumab |
[2] D02802 D02802, D03235 D03235 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 [1] 65 💬 |
153 |
Flebogamma 5% dif |
- |
- |
- |
- |
065 [1] 65 💬 |
154 |
Fludarabina |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 [2] 19, 65 💬 |
155 |
Fludarabina accord |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [1] 65 💬 |
156 |
Fludarabina teva - 25 mg/ml concentrato per soluzione iniettabile o per infusione 1 flaconcino di vetro da 2 ml |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [1] 65 💬 |
157 |
Fludarabine |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
013 [17] 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 💬 |
158 |
Fludarabine monophosphate |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [3] 65, 284, 326 💬 |
159 |
Fludarabine phosphate |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
028 [11] 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285 💬 |
160 |
Fludarabine phosphate 30 mg |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [2] 65, 164 💬 |
161 |
Fludarabine phosphate 40 mg |
Fludarabine |
[2] D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [2] 65, 164 💬 |
162 |
Fludarabine, busulfan, thymoglobulin |
Antithymocyte immunoglobulin (rabbit) |
[3] D00248 D00248, D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [1] 65 💬 |
163 |
Fludarabine, melphalan, thiotepa |
Fludarabine |
[4] D00369 D00369, D00583 D00583, D01907 D01907, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [1] 65 💬 |
164 |
Fortecortin |
- |
- |
- |
- |
028 [2] 28, 65 💬 |
165 |
Fortecortin inject 40 mg amp. |
- |
- |
- |
- |
065 [1] 65 💬 |
166 |
Fucose |
Fucose |
- |
- |
- |
065 [1] 65 💬 |
167 |
G-csf |
Filgrastim |
[1] D03235 D03235 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 [16] 2 , 6 , 11, 13, 16, 47, 49, 51, 60, 62, 65, 85, 96, 284, 285, 331 💬 |
168 |
G-csf for conditioning before hsct. |
Filgrastim |
[1] D03235 D03235 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 [1] 65 💬 |
169 |
G1xcg |
- |
- |
- |
- |
065 [1] 65 💬 |
170 |
G1xcgd transduced cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
171 |
Gadolinium |
Gadolinium |
- |
- |
- |
013 [6] 13, 34, 46, 58, 65, 86 💬 |
172 |
Gadolinium for abdomen |
Gadolinium |
- |
- |
- |
065 [1] 65 💬 |
173 |
Gadolinium for lower back |
Gadolinium |
- |
- |
- |
065 [1] 65 💬 |
174 |
Gammagard liquid |
- |
- |
- |
- |
065 [1] 65 💬 |
175 |
Gammagard s/d (solvent/detergent) |
- |
- |
- |
- |
065 [1] 65 💬 |
176 |
Gammaglobulin |
- |
- |
- |
- |
065 [1] 65 💬 |
177 |
Gammanorm |
- |
- |
- |
- |
014 [2] 14, 65 💬 |
178 |
Gammanorm 165 mg/ml |
- |
- |
- |
- |
065 [1] 65 💬 |
179 |
Gammaplex |
- |
- |
- |
- |
063 [2] 63, 65 💬 |
180 |
Gammaplex (5%) |
- |
- |
- |
- |
065 [1] 65 💬 |
181 |
Gammaplex (intravenous immunoglobulin) |
- |
- |
- |
- |
065 [1] 65 💬 |
182 |
Gammaplex 10 |
- |
- |
- |
- |
065 [1] 65 💬 |
183 |
Gamunex-c |
- |
- |
- |
- |
065 [1] 65 💬 |
184 |
Gcsf |
- |
- |
- |
- |
065 [1] 65 💬 |
185 |
Gene therapy method for cgd |
- |
- |
- |
- |
065 [1] 65 💬 |
186 |
Gene transfer |
- |
- |
- |
- |
065 [1] 65 💬 |
187 |
Gene-transduced autologous cd34+ stem cells |
- |
- |
- |
- |
065 [1] 65 💬 |
188 |
Genetic: cl20-i4-ef1a-h?c-opt |
- |
- |
- |
- |
065 [1] 65 💬 |
189 |
Genetic: infusion of autologous cryopreserved efs-ada lv cd34+ cells (otl-101) |
- |
- |
- |
- |
065 [1] 65 💬 |
190 |
Genetic: infusion of autologous efs-ada lv cd34+ (otl-101) |
- |
- |
- |
- |
065 [1] 65 💬 |
191 |
Genetic: infusion of autologous efs-ada lv cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
192 |
Genetically modified autologous blood stem cells |
- |
- |
- |
- |
065 [1] 65 💬 |
193 |
Glucose |
Dextrose, unspecified form |
- |
- |
- |
002 [15] 2 , 6 , 13, 49, 50, 65, 75, 86, 88, 96, 160, 195, 254, 257, 299 💬 |
194 |
Glycolic acid |
Glycolic acid |
- |
- |
- |
065 [1] 65 💬 |
195 |
Glycosade |
- |
- |
- |
- |
065 [3] 65, 256, 257 💬 |
196 |
Gold |
Gold |
- |
- |
- |
002 [38] 2 , 5 , 6 , 13, 17, 34, 46, 49, 50, 53, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 158, 162, 171, 218, 222, 224, 227, 230, 271, 291, 294, 296, 298, 299, 310, 318 💬 |
197 |
Granulocyte colony stimulating factor |
Filgrastim |
[1] D03235 D03235 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 [6] 2 , 28, 36, 57, 65, 85 💬 |
198 |
Granulocyte colony stimulating factor (g-csf) |
Filgrastim |
[1] D03235 D03235 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 [1] 65 💬 |
199 |
Gtg003.08 |
- |
- |
- |
- |
065 [1] 65 💬 |
200 |
Gvhd prophylaxis |
- |
- |
- |
- |
060 [2] 60, 65 💬 |
201 |
Haemocomplettan p |
- |
- |
- |
- |
065 [1] 65 💬 |
202 |
Haemocomplettan(r) p |
- |
- |
- |
- |
065 [1] 65 💬 |
203 |
Haemocomplettan(r) p 1g/2g |
- |
- |
- |
- |
065 [1] 65 💬 |
204 |
Haplo bm with t cell depletion |
- |
- |
- |
- |
065 [1] 65 💬 |
205 |
Haploidentical hematopoietic cell transplantation |
- |
- |
- |
- |
060 [2] 60, 65 💬 |
206 |
Hematopoetic stem cell transplantation |
- |
- |
- |
- |
019 [5] 19, 65, 120, 160, 326 💬 |
207 |
Hematopoietic stem cell transplant |
- |
- |
- |
- |
065 [1] 65 💬 |
208 |
Hizentra |
- |
- |
- |
- |
014 [4] 14, 50, 51, 65 💬 |
209 |
Hizentra® |
- |
- |
- |
- |
014 [2] 14, 65 💬 |
210 |
Horse -anti-thymocyte |
- |
- |
- |
- |
065 [1] 65 💬 |
211 |
Hpc, a infusion |
- |
- |
- |
- |
060 [2] 60, 65 💬 |
212 |
Htlp |
- |
- |
- |
- |
065 [1] 65 💬 |
213 |
Human fibrinogen |
Fibrinogen human |
- |
- |
- |
065 [1] 65 💬 |
214 |
Human fibrinogen concentrate |
Fibrinogen human |
- |
- |
- |
065 [1] 65 💬 |
215 |
Human immunglobulin g (igg) |
- |
- |
- |
- |
065 [1] 65 💬 |
216 |
Human immunoglobulin |
- |
- |
- |
- |
063 [2] 63, 65 💬 |
217 |
Human immunoglobulin g |
Human immunoglobulin G |
- |
- |
- |
014 [4] 14, 50, 63, 65 💬 |
218 |
Human normal immunoglobulin |
Human immunoglobulin G |
- |
- |
- |
011 [9] 11, 13, 14, 43, 45, 50, 51, 63, 65 💬 |
219 |
Human normal immunoglobulin (iv) |
Human immunoglobulin G |
- |
- |
- |
011 [4] 11, 14, 63, 65 💬 |
220 |
Human normal immunoglobulin (ivig) |
Human immunoglobulin G |
- |
- |
- |
050 [2] 50, 65 💬 |
221 |
Human normal immunoglobulin (subcutaneous - intramuscular immunoglobulin) |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
222 |
Human normal immunoglobulin (subcutaneous) |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
223 |
Human normal immunoglobulin for |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
224 |
Human normal immunoglobulin for intravenous administration |
Human immunoglobulin G |
- |
- |
- |
014 [3] 14, 51, 65 💬 |
225 |
Human normal immunoglobulin for intravenous use |
Human immunoglobulin G |
- |
- |
- |
063 [2] 63, 65 💬 |
226 |
Human normal immunoglobulin for intravenous use (ivig) |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
227 |
Human normal immunoglobulin for subcutaneous administration |
Human immunoglobulin G |
- |
- |
- |
051 [2] 51, 65 💬 |
228 |
Human normal immunoglobulin for subcutaneous administration (igsc) |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
229 |
Human normal immunoglobulin g (igg > 98% purity) |
Human immunoglobulin G |
- |
- |
- |
014 [3] 14, 63, 65 💬 |
230 |
Hyaluronidase |
Hyaluronidase |
[3] D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
028 [4] 28, 51, 65, 331 💬 |
231 |
Hyaluronoglucosaminidase |
Hyaluronidase |
[3] D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 [1] 65 💬 |
232 |
Hydroxyurea |
Hydroxyurea |
[1] D00341 D00341 💬 |
RRM2 [1] RRM2 💬 |
Drug metabolism - other enzymes [6] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
003 [8] 3 , 13, 19, 20, 65, 85, 86, 284 💬 |
233 |
Hyqvia |
- |
- |
- |
- |
014 [2] 14, 65 💬 |
234 |
Hyqvia 100 mg/ml solution for infusion for subcutaneous use |
- |
- |
- |
- |
065 [1] 65 💬 |
235 |
I10e |
- |
- |
- |
- |
014 [3] 14, 63, 65 💬 |
236 |
Ibuprofen |
Ibuprofen |
[4] D00126 D00126, D01122 D01122, D04490 D04490, D06606 D06606 💬 |
PTGS1 [2] PTGS1, PTGS2 💬 |
Alzheimer disease [23] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
013 [6] 13, 46, 65, 113, 271, 299 💬 |
237 |
Ifn-gamma |
- |
- |
- |
- |
065 [1] 65 💬 |
238 |
Ig vena 50 g/l solution for infusion 100 ml vial + infusion set |
- |
- |
- |
- |
063 [2] 63, 65 💬 |
239 |
Igg next generation |
- |
- |
- |
- |
063 [2] 63, 65 💬 |
240 |
Ighy10 |
- |
- |
- |
- |
065 [1] 65 💬 |
241 |
Igiv, 10% |
- |
- |
- |
- |
014 [2] 14, 65 💬 |
242 |
Igiv-c 10% |
- |
- |
- |
- |
065 [1] 65 💬 |
243 |
Ignextgen 16% |
- |
- |
- |
- |
065 [1] 65 💬 |
244 |
Igng |
- |
- |
- |
- |
065 [1] 65 💬 |
245 |
Igpro10 |
- |
- |
- |
- |
014 [3] 14, 51, 65 💬 |
246 |
Igpro20 |
- |
- |
- |
- |
014 [4] 14, 50, 51, 65 💬 |
247 |
Igsc 20% |
- |
- |
- |
- |
065 [1] 65 💬 |
248 |
Igsc 20% 150 mg/kg |
- |
- |
- |
- |
065 [1] 65 💬 |
249 |
Igsc 20% daily push versus 2 times per week pump |
- |
- |
- |
- |
065 [1] 65 💬 |
250 |
Igsc 20% daily push versus every 2 weeks pump |
- |
- |
- |
- |
065 [1] 65 💬 |
251 |
Igsc 20% daily push versus once a week pump |
- |
- |
- |
- |
065 [1] 65 💬 |
252 |
Igsc, 16% |
- |
- |
- |
- |
065 [1] 65 💬 |
253 |
Igsc, 20% |
- |
- |
- |
- |
065 [1] 65 💬 |
254 |
Immune globulin infusion (human), 10% |
- |
- |
- |
- |
065 [1] 65 💬 |
255 |
Immune globulin intravenous |
- |
- |
- |
- |
065 [1] 65 💬 |
256 |
Immune globulin intravenous (human) |
- |
- |
- |
- |
065 [1] 65 💬 |
257 |
Immune globulin intravenous (human) 5% liquid, ivig-sn™ |
- |
- |
- |
- |
065 [1] 65 💬 |
258 |
Immune globulin intravenous (human), 10% |
- |
- |
- |
- |
014 [2] 14, 65 💬 |
259 |
Immune globulin intravenous (human), 10% solution |
- |
- |
- |
- |
065 [1] 65 💬 |
260 |
Immune globulin intravenous (human), 10% tvr (triple virally reduced) solution |
- |
- |
- |
- |
065 [1] 65 💬 |
261 |
Immune globulin intravenous (igiv) |
- |
- |
- |
- |
065 [1] 65 💬 |
262 |
Immune globulin intravenous [human], 10% caprylate/chromatography purified |
- |
- |
- |
- |
065 [1] 65 💬 |
263 |
Immune globulin subcutaneos, 20% |
- |
- |
- |
- |
065 [1] 65 💬 |
264 |
Immune globulin subcutaneous (human) |
- |
- |
- |
- |
014 [2] 14, 65 💬 |
265 |
Immune globulin subcutaneous (human) (scig) |
- |
- |
- |
- |
065 [1] 65 💬 |
266 |
Immune globulin subcutaneous (human), 20% |
- |
- |
- |
- |
065 [1] 65 💬 |
267 |
Immune globulin subcutaneous (human), 20% caprylate/chromatography purified (igsc 20%) |
- |
- |
- |
- |
065 [1] 65 💬 |
268 |
Immune globulin subcutaneous (human), 20% solution |
- |
- |
- |
- |
065 [1] 65 💬 |
269 |
Immune globulin subcutaneous (human), 20%, caprylate/chromatography purified |
- |
- |
- |
- |
065 [1] 65 💬 |
270 |
Immune globulin subcutaneous, 20% |
- |
- |
- |
- |
065 [1] 65 💬 |
271 |
Immune globulin subcutaneous, 20% solution (igsc, 20%) |
- |
- |
- |
- |
065 [1] 65 💬 |
272 |
Immunglobulin (human) |
- |
- |
- |
- |
065 [1] 65 💬 |
273 |
Immunoglobulin g |
- |
- |
- |
- |
011 [7] 11, 13, 14, 49, 50, 63, 65 💬 |
274 |
Immunoglobulin g (ig nextgen 16%) |
- |
- |
- |
- |
065 [1] 65 💬 |
275 |
Immunoglobulin intravenous (human) |
- |
- |
- |
- |
065 [1] 65 💬 |
276 |
Immunoglobulins intravenous (human) |
- |
- |
- |
- |
065 [1] 65 💬 |
277 |
Immunoglobulins, normal human |
- |
- |
- |
- |
065 [1] 65 💬 |
278 |
Immunological diagnosis tests |
- |
- |
- |
- |
065 [1] 65 💬 |
279 |
Immunosuppression only conditioning (ioc) |
- |
- |
- |
- |
065 [1] 65 💬 |
280 |
Immunosuppression only conditioning - closed with amendment l |
- |
- |
- |
- |
065 [1] 65 💬 |
281 |
Increlex |
- |
- |
- |
- |
065 [4] 65, 78, 96, 299 💬 |
282 |
Infliximab |
Infliximab |
[1] D02598 D02598 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
035 [24] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 💬 |
283 |
Inh |
- |
- |
- |
- |
065 [1] 65 💬 |
284 |
Interferon gamma |
Interferon Gamma |
- |
- |
- |
018 [8] 18, 65, 85, 107, 228, 299, 301, 326 💬 |
285 |
Interferon gamma-1b |
Interferon Gamma |
[1] D00747 D00747 💬 |
IFNGR1 [2] IFNGR1, IFNGR2 💬 |
Chagas disease [18] Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
018 [7] 18, 65, 85, 228, 299, 301, 326 💬 |
286 |
Interferon-gamma |
- |
- |
- |
- |
065 [1] 65 💬 |
287 |
Interleukin-2 |
Human interleukin-2 |
- |
- |
- |
002 [8] 2 , 35, 49, 55, 65, 96, 97, 162 💬 |
288 |
Intratect |
- |
- |
- |
- |
013 [3] 13, 35, 65 💬 |
289 |
Intravenous immunoglobulin infusion |
- |
- |
- |
- |
065 [1] 65 💬 |
290 |
Intravenous infusion of transduced cells |
- |
- |
- |
- |
065 [1] 65 💬 |
291 |
Itraconazole |
Itraconazole |
[1] D00350 D00350 💬 |
- |
- |
003 [4] 3 , 65, 227, 299 💬 |
292 |
Iv treatment with igsc, 10% |
- |
- |
- |
- |
065 [1] 65 💬 |
293 |
Ivig |
Human immunoglobulin G |
- |
- |
- |
011 [8] 11, 13, 14, 17, 35, 50, 51, 65 💬 |
294 |
Ivig-peg |
- |
- |
- |
- |
065 [1] 65 💬 |
295 |
Jardiance |
- |
- |
- |
- |
065 [1] 65 💬 |
296 |
Kedrion ivig 10% |
- |
- |
- |
- |
065 [1] 65 💬 |
297 |
Kig10 |
- |
- |
- |
- |
065 [1] 65 💬 |
298 |
Kineret |
- |
- |
- |
- |
028 [9] 28, 41, 46, 49, 65, 106, 107, 266, 299 💬 |
299 |
Kiovig |
- |
- |
- |
- |
014 [2] 14, 65 💬 |
300 |
Kiovig 100 mg/ml solution for infusion |
- |
- |
- |
- |
014 [2] 14, 65 💬 |
301 |
Klh |
- |
- |
- |
- |
013 [2] 13, 65 💬 |
302 |
Kvd900 |
- |
- |
- |
- |
065 [1] 65 💬 |
303 |
Kvd900 100 mg film coated tablet |
- |
- |
- |
- |
065 [1] 65 💬 |
304 |
L-fucose |
Fucose |
- |
- |
- |
065 [1] 65 💬 |
305 |
Ladicell |
- |
- |
- |
- |
065 [1] 65 💬 |
306 |
Ldt |
- |
- |
- |
- |
065 [1] 65 💬 |
307 |
Lemtrada |
- |
- |
- |
- |
013 [2] 13, 65 💬 |
308 |
Leniolisib |
Leniolisib |
[1] D11158 D11158 💬 |
PIK3CA [3] PIK3CA, PIK3CB, PIK3CD 💬 |
AGE-RAGE signaling pathway in diabetic complications [103] AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway |
053 [2] 53, 65 💬 |
309 |
Lenograstim |
Lenograstim |
[1] D03247 D03247 💬 |
CSF3R [1] CSF3R 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 [7] 2 , 13, 16, 18, 19, 57, 65 💬 |
310 |
Lentiviral g1xcgd gene therapy |
- |
- |
- |
- |
065 [1] 65 💬 |
311 |
Lentiviral vector transduced cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
312 |
Lfb-igsc |
- |
- |
- |
- |
065 [1] 65 💬 |
313 |
Mabthera |
- |
- |
- |
- |
011 [22] 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 💬 |
314 |
Mabthera - 2 fiale 100 mg 10 ml |
- |
- |
- |
- |
019 [2] 19, 65 💬 |
315 |
Mavorixafor |
- |
- |
- |
- |
065 [1] 65 💬 |
316 |
Mctls |
- |
- |
- |
- |
065 [1] 65 💬 |
317 |
Melarsoprol |
Melarsoprol |
[1] D00832 D00832 💬 |
- |
- |
065 [1] 65 💬 |
318 |
Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d |
Eflornithine |
[2] D00832 D00832, D07883 D07883 💬 |
ODC1 [1] ODC1 💬 |
Arginine and proline metabolism [3] Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 [1] 65 💬 |
319 |
Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d |
Melarsoprol |
[2] D00832 D00832, D00833 D00833 💬 |
- |
- |
065 [1] 65 💬 |
320 |
Melphalan |
Melphalan |
[1] D00369 D00369 💬 |
- |
- |
011 [15] 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299 💬 |
321 |
Mesna |
- |
- |
- |
- |
011 [11] 11, 13, 44, 45, 49, 51, 60, 65, 85, 96, 164 💬 |
322 |
Methotrexate |
Methotrexate |
[2] D00142 D00142, D02115 D02115 💬 |
DHFR [2] DHFR, DHFR2 💬 |
Antifolate resistance [5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
011 [35] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬 |
323 |
Methylprednisolone |
Methylprednisolone |
[6] D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [44] 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
324 |
Methylprednisolone or prednisolone |
Methylprednisolone |
[14] D00407 D00407, D00472 D00472, D00751 D00751, D00979 D00979, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
065 [1] 65 💬 |
325 |
Mmf |
- |
- |
- |
- |
013 [13] 13, 35, 40, 49, 50, 51, 60, 65, 66, 222, 224, 226, 299 💬 |
326 |
Monitor |
Methamidophos |
- |
- |
- |
002 [18] 2 , 11, 13, 19, 46, 49, 58, 65, 70, 85, 86, 98, 113, 118, 129, 298, 299, 300 💬 |
327 |
Mozobil |
- |
- |
- |
- |
019 [3] 19, 65, 285 💬 |
328 |
Mozobil - 20 mg/ml - soluzione iniettabile - uso sottocutaneo - flaconcino (vetro) - 24 mg/1.2 ml 1 flaconcino |
- |
- |
- |
- |
065 [1] 65 💬 |
329 |
Mozobil 20mg/ml vial (injectable solution for subcutaneous use) |
- |
- |
- |
- |
065 [1] 65 💬 |
330 |
Mozobil 20mg/ml vial (injectable solution, subcutaneous use) |
- |
- |
- |
- |
065 [1] 65 💬 |
331 |
Mozobil, |
- |
- |
- |
- |
065 [1] 65 💬 |
332 |
Mycophenolate |
Mycophenolic acid |
[1] D05096 D05096 💬 |
IMPDH1 [2] IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes [3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 [34] 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬 |
333 |
Mycophenolate mofetil |
Mycophenolate mofetil |
[4] D00752 D00752, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 [2] IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes [3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 [32] 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬 |
334 |
Mycophenolate mofetil (mmf) |
Mycophenolate mofetil |
[4] D00752 D00752, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 [2] IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes [3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
013 [7] 13, 49, 51, 60, 65, 66, 222 💬 |
335 |
Myeloablative conditioning-closed with amendment l |
- |
- |
- |
- |
065 [1] 65 💬 |
336 |
Myeloablative preparative regimen |
- |
- |
- |
- |
062 [3] 62, 65, 284 💬 |
337 |
Myelostim |
- |
- |
- |
- |
065 [1] 65 💬 |
338 |
Myelostim - 34 1 flaconcino liofilizzato 33.6 miu + siringa preriempita solvente 1 ml |
- |
- |
- |
- |
019 [2] 19, 65 💬 |
339 |
Myelostim 34 milions ui/ml - powder and solvent for solution for injection/infusion |
- |
- |
- |
- |
065 [1] 65 💬 |
340 |
Myelostim 34 milions ui/ml, powder and solvent for solution for injection or infusion |
- |
- |
- |
- |
065 [1] 65 💬 |
341 |
Nanogam 100 mg/ml |
- |
- |
- |
- |
065 [1] 65 💬 |
342 |
Nanogam® 50 mg/ml |
- |
- |
- |
- |
065 [1] 65 💬 |
343 |
Ndv-3a |
- |
- |
- |
- |
065 [1] 65 💬 |
344 |
Neopterin |
Neopterin |
- |
- |
- |
065 [1] 65 💬 |
345 |
Newgam |
- |
- |
- |
- |
014 [3] 14, 63, 65 💬 |
346 |
Newnorm |
- |
- |
- |
- |
065 [1] 65 💬 |
347 |
Nifurtimox |
Nifurtimox |
[1] D00833 D00833 💬 |
- |
- |
065 [1] 65 💬 |
348 |
Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d |
Eflornithine |
[2] D00833 D00833, D07883 D07883 💬 |
ODC1 [1] ODC1 💬 |
Arginine and proline metabolism [3] Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 [1] 65 💬 |
349 |
Nifurtimox-eflronithine combination treatment (nect) |
Nifurtimox |
[1] D00833 D00833 💬 |
- |
- |
065 [1] 65 💬 |
350 |
None |
- |
- |
- |
- |
046 [14] 46, 65, 78, 84, 85, 96, 97, 140, 160, 161, 171, 231, 271, 299 💬 |
351 |
Normal human immunoglobulin g |
Human immunoglobulin G |
- |
- |
- |
065 [1] 65 💬 |
352 |
Noxafil |
- |
- |
- |
- |
060 [3] 60, 65, 299 💬 |
353 |
Noxafil 40 mg/ml oral solution |
- |
- |
- |
- |
065 [1] 65 💬 |
354 |
Octa-c1-inh |
Human C1-esterase inhibitor |
- |
- |
- |
065 [1] 65 💬 |
355 |
Octagam |
- |
- |
- |
- |
013 [2] 13, 65 💬 |
356 |
Octagam 10% |
- |
- |
- |
- |
050 [3] 50, 63, 65 💬 |
357 |
Octagam 5% |
- |
- |
- |
- |
013 [2] 13, 65 💬 |
358 |
Octagam 50 mg/ml oldatos infúzió |
- |
- |
- |
- |
065 [1] 65 💬 |
359 |
Octanorm |
- |
- |
- |
- |
050 [2] 50, 65 💬 |
360 |
Octanorm 16.5% |
- |
- |
- |
- |
050 [2] 50, 65 💬 |
361 |
Omalizumab |
Omalizumab |
[1] D05251 D05251 💬 |
FCER1A [1] FCER1A 💬 |
Asthma [4] Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
046 [7] 46, 53, 65, 98, 162, 226, 299 💬 |
362 |
Omalizumab (xolair) |
Omalizumab |
[1] D05251 D05251 💬 |
FCER1A [1] FCER1A 💬 |
Asthma [4] Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
065 [1] 65 💬 |
363 |
Orencia |
- |
- |
- |
- |
044 [13] 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 160, 222, 271 💬 |
364 |
Orencia® 125 mg solution for injection in pre-filled syringe |
- |
- |
- |
- |
065 [1] 65 💬 |
365 |
Other hematological agents |
- |
- |
- |
- |
065 [1] 65 💬 |
366 |
Other: |
- |
- |
- |
- |
002 [2] 2 , 65 💬 |
367 |
Other: 0.9% sodium chloride |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
065 [1] 65 💬 |
368 |
Other: blood sampling for laboratory developed test (ldt) analysis |
- |
- |
- |
- |
065 [1] 65 💬 |
369 |
Other: cultured thymus tissue implantation and parental parathyroid transplantation |
- |
- |
- |
- |
065 [1] 65 💬 |
370 |
Other: cultured thymus tissue implantation with parathyroid transplantation |
- |
- |
- |
- |
065 [1] 65 💬 |
371 |
Other: donor lymphocyte infusion |
- |
- |
- |
- |
065 [1] 65 💬 |
372 |
Other: food diary |
- |
- |
- |
- |
065 [1] 65 💬 |
373 |
Other: haematopoietic stem cell transplantation (hsct) |
- |
- |
- |
- |
065 [1] 65 💬 |
374 |
Other: laboratory biomarker analysis |
- |
- |
- |
- |
011 [21] 11, 13, 14, 16, 26, 28, 34, 49, 51, 60, 62, 65, 89, 96, 97, 232, 283, 284, 285, 298, 331 💬 |
375 |
Other: medical history questionnaires |
- |
- |
- |
- |
065 [1] 65 💬 |
376 |
Other: modified mixed meal tolerance test |
- |
- |
- |
- |
065 [1] 65 💬 |
377 |
Other: modified oral glucose tolerance test |
Dextrose, unspecified form |
- |
- |
- |
065 [1] 65 💬 |
378 |
Other: palliative care |
- |
- |
- |
- |
019 [5] 19, 65, 120, 160, 326 💬 |
379 |
Otl-101 |
- |
- |
- |
- |
065 [1] 65 💬 |
380 |
Otl-103 |
- |
- |
- |
- |
065 [1] 65 💬 |
381 |
Otl-103 dispersion for infusion |
- |
- |
- |
- |
065 [1] 65 💬 |
382 |
Ovastat |
Treosulfan |
[1] D07253 D07253 💬 |
- |
- |
013 [2] 13, 65 💬 |
383 |
Ovastat 1000 |
Treosulfan |
[1] D07253 D07253 💬 |
- |
- |
013 [2] 13, 65 💬 |
384 |
Ovastat 1000 (treosulfan injection) |
Treosulfan |
[1] D07253 D07253 💬 |
- |
- |
065 [1] 65 💬 |
385 |
Ovastat 1000 mg, powder for solution for infusion |
Treosulfan |
[1] D07253 D07253 💬 |
- |
- |
065 [1] 65 💬 |
386 |
Ovastat 5000 |
Treosulfan |
[1] D07253 D07253 💬 |
- |
- |
013 [2] 13, 65 💬 |
387 |
Ovastat 5000 (treosulfan injection) |
Treosulfan |
[1] D07253 D07253 💬 |
- |
- |
065 [1] 65 💬 |
388 |
Ovastat 5000 mg, powder for solution for infusion |
Treosulfan |
[1] D07253 D07253 💬 |
- |
- |
065 [1] 65 💬 |
389 |
Palifermin |
Palifermin |
[1] D05338 D05338 💬 |
FGFR2 [1] FGFR2 💬 |
Calcium signaling pathway [13] Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells |
013 [4] 13, 38, 39, 65 💬 |
390 |
Pantoprazole |
Pantoprazole |
[2] D02593 D02593, D05353 D05353 💬 |
ATP4A [2] ATP4A, ATP4B 💬 |
Collecting duct acid secretion [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
013 [2] 13, 65 💬 |
391 |
Pantoprazolo 20 mg gastro-resistant tablets |
- |
- |
- |
- |
065 [1] 65 💬 |
392 |
Peg |
- |
- |
- |
- |
006 [9] 6 , 13, 46, 65, 78, 96, 97, 240, 299 💬 |
393 |
Peg-ada |
- |
- |
- |
- |
065 [1] 65 💬 |
394 |
Peg-ada ert |
- |
- |
- |
- |
065 [1] 65 💬 |
395 |
Peg-interleukin-2 |
Human interleukin-2 |
- |
- |
- |
065 [1] 65 💬 |
396 |
Pentamidine |
Pentamidine |
[2] D00834 D00834, D08333 D08333 💬 |
- |
- |
065 [1] 65 💬 |
397 |
Peripheral blood stem cells |
- |
- |
- |
- |
051 [2] 51, 65 💬 |
398 |
Pha-022121 |
- |
- |
- |
- |
065 [1] 65 💬 |
399 |
Phagocyte oxidase subunit transduced cd34 hematopoietic stem cells |
- |
- |
- |
- |
065 [1] 65 💬 |
400 |
Phosphate |
Phosphate ion |
- |
- |
- |
002 [30] 2 , 3 , 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 276, 283, 284, 285, 286, 299 💬 |
401 |
Pid |
- |
- |
- |
- |
065 [1] 65 💬 |
402 |
Pioglitazone |
Pioglitazone |
[2] D00945 D00945, D08378 D08378 💬 |
PPARG [1] PPARG 💬 |
AMPK signaling pathway [9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
002 [17] 2 , 6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬 |
403 |
Plerixafor |
Plerixafor |
[1] D08971 D08971 💬 |
CXCR4 [1] CXCR4 💬 |
Axon guidance [12] Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
020 [5] 20, 51, 65, 285, 299 💬 |
404 |
Plerixafor for conditioning before hsct. |
Plerixafor |
[1] D08971 D08971 💬 |
CXCR4 [1] CXCR4 💬 |
Axon guidance [12] Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
065 [1] 65 💬 |
405 |
Pncj pps |
- |
- |
- |
- |
065 [1] 65 💬 |
406 |
Pneumo 23 |
- |
- |
- |
- |
065 [1] 65 💬 |
407 |
Polyclonal igg |
- |
- |
- |
- |
065 [1] 65 💬 |
408 |
Posaconazole |
Posaconazole |
[1] D02555 D02555 💬 |
- |
- |
060 [3] 60, 65, 299 💬 |
409 |
Posaconazole (psz) |
Posaconazole |
[1] D02555 D02555 💬 |
- |
- |
065 [1] 65 💬 |
410 |
Pps |
- |
- |
- |
- |
065 [1] 65 💬 |
411 |
Prednisolone |
Prednisolone |
[8] D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
011 [40] 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬 |
412 |
Prednisone |
Prednisone |
[1] D00473 D00473 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [47] 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 |
413 |
Prevenar |
- |
- |
- |
- |
065 [1] 65 💬 |
414 |
Privigen |
- |
- |
- |
- |
011 [4] 11, 14, 51, 65 💬 |
415 |
Privigen® |
- |
- |
- |
- |
014 [3] 14, 63, 65 💬 |
416 |
Procedure: allo bmt |
- |
- |
- |
- |
065 [1] 65 💬 |
417 |
Procedure: allogeneic bone marrow transplantation |
- |
- |
- |
- |
060 [6] 60, 65, 96, 164, 284, 285 💬 |
418 |
Procedure: allogeneic hematopoietic stem cell transplantation |
- |
- |
- |
- |
028 [8] 28, 51, 60, 62, 65, 164, 284, 285 💬 |
419 |
Procedure: allogeneic hsc |
- |
- |
- |
- |
065 [1] 65 💬 |
420 |
Procedure: allogeneic hsct |
- |
- |
- |
- |
065 [1] 65 💬 |
421 |
Procedure: blood draw |
- |
- |
- |
- |
006 [5] 6 , 19, 65, 231, 299 💬 |
422 |
Procedure: blood sample |
- |
- |
- |
- |
065 [1] 65 💬 |
423 |
Procedure: ct scan |
- |
- |
- |
- |
065 [1] 65 💬 |
424 |
Procedure: cyclophosphamide |
Cyclophosphamide |
[2] D00287 D00287, D07760 D07760 💬 |
- |
- |
065 [1] 65 💬 |
425 |
Procedure: hematopoietic stem cell transplantation |
- |
- |
- |
- |
013 [3] 13, 65, 285 💬 |
426 |
Procedure: in vitro-treated peripheral blood stem cell transplantation |
- |
- |
- |
- |
060 [2] 60, 65 💬 |
427 |
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation |
- |
- |
- |
- |
028 [6] 28, 51, 60, 62, 65, 285 💬 |
428 |
Procedure: peripheral blood stem cell transplantation |
- |
- |
- |
- |
011 [11] 11, 13, 14, 28, 51, 60, 62, 65, 283, 284, 285 💬 |
429 |
Procedure: stem cell infusion |
- |
- |
- |
- |
028 [5] 28, 60, 65, 284, 285 💬 |
430 |
Procedure: stem cell transplant |
- |
- |
- |
- |
019 [5] 19, 20, 65, 164, 284 💬 |
431 |
Procedure: stem cell transplantation |
- |
- |
- |
- |
019 [6] 19, 51, 60, 62, 65, 326 💬 |
432 |
Procedure: total body irradiation |
- |
- |
- |
- |
019 [6] 19, 20, 51, 60, 65, 285 💬 |
433 |
Procedure: total lymphoid irradiation |
- |
- |
- |
- |
065 [3] 65, 284, 326 💬 |
434 |
Procedure: umbilical cord blood transplantation |
- |
- |
- |
- |
060 [5] 60, 65, 284, 285, 326 💬 |
435 |
Proleukin |
- |
- |
- |
- |
002 [3] 2 , 49, 65 💬 |
436 |
Proleukin® s |
- |
- |
- |
- |
065 [1] 65 💬 |
437 |
Promacta |
- |
- |
- |
- |
063 [2] 63, 65 💬 |
438 |
Prometic's immune globulin intravenous 10% |
- |
- |
- |
- |
065 [1] 65 💬 |
439 |
Psrs11.efs.il2rg.pre* retroviral vector |
- |
- |
- |
- |
065 [1] 65 💬 |
440 |
Psrs11.efs.il2rg.pre* retroviral vector transduce |
- |
- |
- |
- |
065 [1] 65 💬 |
441 |
Psrs11.efs.il2rg.pre* retroviral vector transduced cells |
- |
- |
- |
- |
065 [1] 65 💬 |
442 |
Pth |
- |
- |
- |
- |
065 [2] 65, 235 💬 |
443 |
Pth 1-34 |
Teriparatide |
[1] D06078 D06078 💬 |
PTH1R [1] PTH1R 💬 |
Endocrine and other factor-regulated calcium reabsorption [3] Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
065 [2] 65, 235 💬 |
444 |
Purified vero cell vaccine) |
- |
- |
- |
- |
065 [1] 65 💬 |
445 |
Pyrimethamine |
Pyrimethamine |
[1] D00488 D00488 💬 |
- |
- |
002 [4] 2 , 4 , 19, 65 💬 |
446 |
R-hil-18bp |
- |
- |
- |
- |
065 [1] 65 💬 |
447 |
Rabbit |
Rabbit |
- |
- |
- |
011 [8] 11, 13, 49, 51, 60, 65, 96, 285 💬 |
448 |
Rabbit anti-thymocyte globulin |
Rabbit |
- |
- |
- |
049 [2] 49, 65 💬 |
449 |
Radiation: radiation therapy |
- |
- |
- |
- |
034 [5] 34, 60, 65, 284, 285 💬 |
450 |
Radiation: total body 200cgy |
- |
- |
- |
- |
065 [1] 65 💬 |
451 |
Radiation: total body irradiation |
- |
- |
- |
- |
036 [7] 36, 49, 51, 60, 65, 283, 284 💬 |
452 |
Radiation: total body irradiation (tbi) |
- |
- |
- |
- |
060 [3] 60, 65, 285 💬 |
453 |
Radiation: total lymphoid irradiation (tli) |
- |
- |
- |
- |
060 [2] 60, 65 💬 |
454 |
Radiation: total-body irradiation |
- |
- |
- |
- |
028 [9] 28, 51, 60, 62, 65, 96, 283, 284, 285 💬 |
455 |
Rag1 lv cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
456 |
Ranitidine |
Ranitidine |
[2] D00422 D00422, D00673 D00673 💬 |
HRH2 [1] HRH2 💬 |
Calcium signaling pathway [3] Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
013 [2] 13, 65 💬 |
457 |
Recombinant human hyaluronidase |
Hyaluronidase |
[3] D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
028 [2] 28, 65 💬 |
458 |
Recombinant human hyaluronidase (rhuph20) |
Hyaluronidase |
[3] D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 [1] 65 💬 |
459 |
Recombinant human hyaluronidase (rhuph20)+ immune globulin intravenous (igiv) |
Hyaluronidase |
[3] D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 [1] 65 💬 |
460 |
Recombinant human hyaluronidase + immune globulin intravenous |
Hyaluronidase |
[3] D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 [1] 65 💬 |
461 |
Reduced intensity conditioning |
- |
- |
- |
- |
019 [2] 19, 65 💬 |
462 |
Reduced intensity conditioning (ric) |
- |
- |
- |
- |
065 [1] 65 💬 |
463 |
Reduced intensity preparative regimen |
- |
- |
- |
- |
062 [3] 62, 65, 284 💬 |
464 |
Reduced toxicity ablative regimen |
- |
- |
- |
- |
062 [3] 62, 65, 284 💬 |
465 |
Retroviral sf71-gp91phox transduced cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
466 |
Retrovirus-mediated gene transfer |
- |
- |
- |
- |
065 [1] 65 💬 |
467 |
Rhucd40l |
- |
- |
- |
- |
065 [1] 65 💬 |
468 |
Ri-002 |
- |
- |
- |
- |
065 [1] 65 💬 |
469 |
Rifaximin |
Rifaximin |
[1] D02554 D02554 💬 |
- |
- |
006 [6] 6 , 65, 96, 97, 99, 296 💬 |
470 |
Rimiducid |
Rimiducid |
[1] D11195 D11195 💬 |
CASP9 [1] CASP9 💬 |
Alzheimer disease [34] Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Colorectal cancer, Endometrial cancer, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Huntington disease, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Measles, Non-small cell lung cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parkinson disease, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prion disease, Prostate cancer, Small cell lung cancer, Thyroid hormone signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Viral myocarditis, p53 signaling pathway |
019 [6] 19, 60, 65, 284, 285, 326 💬 |
471 |
Rituximab |
Rituximab |
[1] D02994 D02994 💬 |
MS4A1 [1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
011 [47] 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
472 |
Rituximab (rtx) and azathioprine (aza) |
Azathioprine |
[3] D00238 D00238, D02994 D02994, D03033 D03033 💬 |
MS4A1 [1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
065 [1] 65 💬 |
473 |
Rivogenlecleucel |
- |
- |
- |
- |
019 [6] 19, 60, 65, 284, 285, 326 💬 |
474 |
Romiplostim |
Romiplostim |
[1] D08990 D08990 💬 |
MPL [1] MPL 💬 |
Cytokine-cytokine receptor interaction [2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway |
060 [4] 60, 63, 64, 65 💬 |
475 |
Rp-l201 |
- |
- |
- |
- |
065 [1] 65 💬 |
476 |
Rtx |
- |
- |
- |
- |
011 [4] 11, 65, 222, 240 💬 |
477 |
Sc treatment with igsc, 10% with rhuph20 followed by iv/igsc, 10% only (safety) |
- |
- |
- |
- |
065 [1] 65 💬 |
478 |
Sc treatment with igsc, 10% with rhuph20 followed by sc/igsc, 10% only (safety) |
- |
- |
- |
- |
065 [1] 65 💬 |
479 |
Scid screening |
- |
- |
- |
- |
065 [1] 65 💬 |
480 |
Scyx-7158 |
SCYX-7158 |
- |
- |
- |
065 [1] 65 💬 |
481 |
Sirolimus |
Sirolimus |
[1] D00753 D00753 💬 |
MTOR [1] MTOR 💬 |
AMPK signaling pathway [50] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
006 [35] 6 , 13, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 💬 |
482 |
Sodium chloride |
Chloride ion |
[1] D02056 D02056 💬 |
- |
- |
006 [20] 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 168, 193, 227, 228, 271, 288, 299 💬 |
483 |
Somatic gene-therapy by x-cgd |
- |
- |
- |
- |
065 [1] 65 💬 |
484 |
Sta-5326 |
- |
- |
- |
- |
065 [2] 65, 96 💬 |
485 |
Stelara (ustekinumab) |
Ustekinumab |
[1] D09214 D09214 💬 |
IL12A [3] IL12A, IL12B, IL23A 💬 |
African trypanosomiasis [26] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
065 [1] 65 💬 |
486 |
Stem cell transplant |
- |
- |
- |
- |
060 [2] 60, 65 💬 |
487 |
Stem cell transplantation |
- |
- |
- |
- |
013 [10] 13, 19, 20, 46, 65, 90, 125, 164, 234, 326 💬 |
488 |
Strimvelis |
- |
- |
- |
- |
065 [1] 65 💬 |
489 |
Subcuvia |
- |
- |
- |
- |
014 [3] 14, 49, 65 💬 |
490 |
Subgam |
- |
- |
- |
- |
065 [1] 65 💬 |
491 |
Sulfadoxine |
Sulfadoxine |
[1] D00580 D00580 💬 |
- |
- |
065 [1] 65 💬 |
492 |
Suspension of autologous cd34+cells transduced with the g1xcgd viral vector |
- |
- |
- |
- |
065 [1] 65 💬 |
493 |
T-cell depleted & cd34+select/w/stemcell enriched product |
- |
- |
- |
- |
065 [1] 65 💬 |
494 |
Tabelecleucel |
- |
- |
- |
- |
065 [1] 65 💬 |
495 |
Tablets fexinidazole |
Fexinidazole |
[1] D11252 D11252 💬 |
- |
- |
065 [1] 65 💬 |
496 |
Tacrolimus |
Tacrolimus |
[2] D00107 D00107, D08556 D08556 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
002 [32] 2 , 6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬 |
497 |
Tacrolimus (tacro) |
Tacrolimus |
[2] D00107 D00107, D08556 D08556 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
065 [1] 65 💬 |
498 |
Tadekinig alfa |
Tadekinig alfa |
- |
- |
- |
065 [1] 65 💬 |
499 |
Tbx-1400 |
- |
- |
- |
- |
065 [1] 65 💬 |
500 |
Tcr alfa beta t cell depletion |
- |
- |
- |
- |
065 [1] 65 💬 |
501 |
Thalidomide |
Thalidomide |
[1] D00754 D00754 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
002 [20] 2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬 |
502 |
Therapeutic allogeneic lymphocytes |
- |
- |
- |
- |
060 [3] 60, 65, 285 💬 |
503 |
There is no recommended inn |
- |
- |
- |
- |
065 [1] 65 💬 |
504 |
Thiotepa |
Thiotepa |
[1] D00583 D00583 💬 |
- |
- |
013 [11] 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 💬 |
505 |
Thiotepa--escalated dose |
Thiotepa |
[1] D00583 D00583 💬 |
- |
- |
019 [4] 19, 20, 65, 284 💬 |
506 |
Thiotepa--single daily dose |
Thiotepa |
[1] D00583 D00583 💬 |
- |
- |
019 [4] 19, 20, 65, 284 💬 |
507 |
Thymoglobulin |
Antithymocyte immunoglobulin (rabbit) |
- |
- |
- |
036 [6] 36, 51, 60, 65, 96, 326 💬 |
508 |
Thymus tissue for transplantation |
- |
- |
- |
- |
065 [1] 65 💬 |
509 |
Thymus/parathyroid transplantation |
- |
- |
- |
- |
065 [2] 65, 235 💬 |
510 |
Traditional treatment of cgd and tb |
- |
- |
- |
- |
065 [1] 65 💬 |
511 |
Transduced lymphocytes |
- |
- |
- |
- |
065 [1] 65 💬 |
512 |
Transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
513 |
Transplant conditioning with mobilization and alemtuzumab |
Alemtuzumab |
[1] D02802 D02802 💬 |
- |
- |
065 [1] 65 💬 |
514 |
Transplant conditioning with mobilization only |
- |
- |
- |
- |
065 [1] 65 💬 |
515 |
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan |
Alemtuzumab |
[5] D00369 D00369, D00583 D00583, D01907 D01907, D02802 D02802, D07966 D07966 💬 |
RRM1 [1] RRM1 💬 |
Drug metabolism - other enzymes [5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 [2] 65, 164 💬 |
516 |
Treosulfan |
Treosulfan |
[1] D07253 D07253 💬 |
- |
- |
013 [3] 13, 19, 65 💬 |
517 |
Tyf-il-2rg gene-modified autologous stem cells |
- |
- |
- |
- |
065 [1] 65 💬 |
518 |
Unrelated bm with t cell depletion |
- |
- |
- |
- |
065 [1] 65 💬 |
519 |
Unrelated cord blood |
- |
- |
- |
- |
065 [1] 65 💬 |
520 |
Ustekinumab |
Ustekinumab |
[1] D09214 D09214 💬 |
IL12A [3] IL12A, IL12B, IL23A 💬 |
African trypanosomiasis [26] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
037 [15] 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬 |
521 |
Valacyclovir |
Valaciclovir |
[3] D00398 D00398, D08664 D08664, D10518 D10518 💬 |
- |
- |
065 [1] 65 💬 |
522 |
Valproic acid |
Valproic acid |
[1] D00399 D00399 💬 |
ABAT [7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 |
Alanine, aspartate and glutamate metabolism [17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
003 [10] 3 , 5 , 26, 34, 65, 89, 90, 222, 256, 331 💬 |
523 |
Verorab® (pvrv |
- |
- |
- |
- |
065 [1] 65 💬 |
524 |
Vigantol |
- |
- |
- |
- |
013 [4] 13, 65, 96, 97 💬 |
525 |
Vitamin d3 |
Cholecalciferol |
[1] D00188 D00188 💬 |
VDR [1] VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption [4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
006 [11] 6 , 13, 20, 46, 49, 53, 60, 65, 96, 97, 299 💬 |
526 |
Vivaglobin |
- |
- |
- |
- |
014 [2] 14, 65 💬 |
527 |
Vm106 |
- |
- |
- |
- |
065 [1] 65 💬 |
528 |
Water |
Water |
[1] D00001 D00001 💬 |
- |
- |
002 [22] 2 , 5 , 6 , 13, 17, 19, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 💬 |
529 |
X4p-001 |
- |
- |
- |
- |
065 [1] 65 💬 |
530 |
Xifaxan |
- |
- |
- |
- |
065 [2] 65, 94 💬 |
531 |
Zarzio |
- |
- |
- |
- |
065 [2] 65, 285 💬 |
532 |
Zoledronate |
Zoledronic acid |
[4] D01968 D01968, D06378 D06378, D06379 D06379, D08689 D08689 💬 |
FDPS [1] FDPS 💬 |
Human T-cell leukemia virus 1 infection [4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
046 [2] 46, 65 💬 |